Germany to invest 300 million euros in a firm developing COVID-19 vaccine
To develop COVID-19’s vaccine further, Germany will be taking a stake of about 23% in an unlisted biotech firm CureVac by investing 300 million euros ($377 million) capital. The decision was taken by SAP co-founder Dietmar Hopp – who is an early investor and owner of a stake of more than 80% in CureVac, said … Read more